Subscribe to Newsletter

Jan van de Winkel

CEO, Genmab

Van de Winkel co-founded Genmab in 1999 with the goal of unlocking the power of antibodies to make an impact on people’s lives. Through his leadership, Genmab’s innovations have led to six approved medicines to treat cancer and other serious diseases. Two of the seven bispecific (dual targeting) antibody medicines currently approved in the US and Europe incorporate Genmab’s DuoBody bispecific technology, a platform that Van de Winkel co-invented. Described as a visionary in the industry, Van de Winkel has authored more than 300 scientific publications and has been responsible for over 180 patents and patent applications. He is also passionate about young scientists and teaches an annual immunotherapy course at Utrecht University.

We asked…

What has been the biggest breakthrough in biopharma in recent years?

Bispecific (dual-targeting) antibodies have made significant advances as next-generation medicines in recent years, and I am extremely optimistic about the potential benefits of these targeted therapies for people with cancer and other serious illnesses. At Genmab, we strive to unlock the full potential of our “knock-your-socks-off” (KYSO) antibody medicines to make an impact on patients’ lives. 

Part of the Power List The Power List 2022

Find out more

The Power List 2022 focuses on the top 10 VIPs in three key categories of medicine making

Go to The Power List 2022

Part of the Power List 2021

Find out more

Welcome to our annual celebration of the great and inspirational minds that contribute to the development and manufacture of new medicinal products

Go to The Power List 2021

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine